What is AMLX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 3.37B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for AMLX?

P/E (TTM) is n/a and 52-week range is $10.83 to $41.14 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s AMLX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for AMLX?

The company profile lists revenue (TTM) near $196M, net income (TTM) near $-18.58B, EPS (TTM) near $-1.43 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Amylyx Pharmaceuticals Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Cambridge, Massachusetts, US, 111.2M shares outstanding, ISIN US03237H1014 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Amylyx Pharmaceuticals Inc

$AMLX

Health Care · Pharmaceuticals

IR Run Scenarios

$26.85

-2.29%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Amylyx Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of therapies for diseases with significant unmet medical need, with an emphasis on endocrine and neurodegenerative disorders. The company is headquartered in Cambridge, Massachusetts and currently employs 136 full-time employees. The company went IPO on 2022-01-07. The firm is focused on four investigational therapies across several diseases. Its lead investigational asset is avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. Avexitide has been evaluated as a treatment for Post-Bariatric Hypoglycemia (PBH) and congenital HI, two indications characterized by hyperinsulinemic hypoglycemia. In addition to avexitide, it is advancing AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in Wolfram syndrome, AMX0114 in amyotrophic lateral sclerosis (ALS), and AMX0318 in PBH and other rare diseases. AMX0035 is designed to mitigate neurodegeneration by targeting endoplasmic reticulum stress and mitochondrial dysfunction, two cellular processes central to neuronal cell death and neurodegeneration. AMX0114 is an investigational antisense oligonucleotide and AMX0318 is a novel GLP-1 receptor antagonist.

Employees

136

Website

www.amylyx.com/

IPO

2022-01-07

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)